Galapagos will gain full development and commercialization rights to its pipeline, and is subject to single digit royalty ...
Galapagos NV plans to split into two entities by mid-2025, focusing on oncology cell therapy and innovative medicines, with ...
Belgian biotech company Galapagos NV plans to spin off part of its operations, creating a new listed firm with approximately ...
SpinCo will be a pure-play news ... the average analyst target price for CMCSA stock is $48.17, representing implied upside of roughly 13% to current levels. Additionally, the consensus ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback